Related references
Note: Only part of the references are listed.Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
April W. Armstrong et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2023)
Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis
Ian M. Catlett et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)
Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study
Christopher Tehlirian et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study
Christopher Tehlirian et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study
Ravi Shankar P. Singh et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Kamran Ghoreschi et al.
LANCET (2021)
Are there thresholds of conflict of interest with gifts from industry? Comment on the article by Wayant et al
Jeffrey R. Curtis et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Irradiation Haematopoiesis Recovery Orchestrated by IL-12/IL-12Rβ1/TYK2/STAT3-Initiated Osteogenic Differentiation of Mouse Bone Marrow-Derived Mesenchymal Stem Cells
Fengjie Li et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
Anjaneya Chimalakonda et al.
DERMATOLOGY AND THERAPY (2021)
Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study
Christopher Tehlirian et al.
LANCET RHEUMATOLOGY (2021)
JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
Miguel Nogueira et al.
DRUGS (2020)
Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis
Pablo Olivera et al.
GASTROENTEROLOGY (2020)
Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis
Karen M. Page et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study
Abby S. Van Voorhees et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis A Review
April W. Armstrong et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial
Seth B. Forman et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)
Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases
Brian S. Gerstenberger et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
New Treatment Addressing the Pathogenesis of Psoriasis
Michio Tokuyama et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
15026 BMS-986165, an oral selective tyrosine kinase 2 inhibitor: Evaluation of changes in laboratory parameters in response to treatment in a phase 2 trial in psoriasis
Kenneth Gordon et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
NK Cells Require Cell-Extrinsic and -Intrinsic TYK2 for Full Functionality in Tumor Surveillance and Antibacterial Immunity
Natalija Simonovic et al.
JOURNAL OF IMMUNOLOGY (2019)
Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists
Tamara Perez-Jeldres et al.
FRONTIERS IN PHARMACOLOGY (2019)
JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?
Silvio Danese et al.
GUT (2019)
Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain
James R. Burke et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Targeting the Janus Kinase Family in Autoimmune Skin Diseases
Michael D. Howell et al.
FRONTIERS IN IMMUNOLOGY (2019)
Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018)
Xingrui He et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2019)
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis
Christopher Banfield et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints
Marie-Astrid Boutet et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Topical Janus kinase inhibitors: A review of applications in dermatology
Anna-Marie Hosking et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Daniel E. Johnson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
The interleukin-23/interleukin-17 Axis Links Adaptive and innate immunity in Psoriasis
Michael P. Schoen et al.
FRONTIERS IN IMMUNOLOGY (2018)
Tofacitinib for the treatment of psoriasis and psoriatic arthritis
Anna Berekmeri et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)
Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis
Jason E. Hawkes et al.
JOURNAL OF IMMUNOLOGY (2018)
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
Kim Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A systematic review of worldwide epidemiology of psoriasis
I. M. Michalek et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Psoriasis pathogenesis and the development of novel targeted immune therapies
Jason E. Hawkes et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition
Robert Bissonnette et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2017)
Herpes zoster in psoriasis patients treated with tofacitinib
Kevin L. Winthrop et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Daniella M. Schwartz et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
The emerging safety profile of JAK inhibitors in rheumatic disease
Kevin L. Winthrop
NATURE REVIEWS RHEUMATOLOGY (2017)
Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry
Alan Menter et al.
DERMATOLOGY AND THERAPY (2017)
Mechanisms and consequences of Jak-STAT signaling in the immune system
Alejandro V. Villarino et al.
NATURE IMMUNOLOGY (2017)
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Daniella M. Schwartz et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Tyrosine kinase 2 is not limiting human antiviral type III interferon responses
Sebastian Fuchs et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2016)
Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity
Calliope A. Dendrou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments
Fenglong Xie et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Psoriasis
Jacqueline E. Greb et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
John J. O'Shea et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition
Christoph Garbers et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
IL-6 as a keystone cytokine in health and disease
Christopher A. Hunter et al.
NATURE IMMUNOLOGY (2015)
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Robert E. Kalb et al.
JAMA DERMATOLOGY (2015)
Interferon-Stimulated Genes: A Complex Web of Host Defenses
William M. Schneider et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 32 (2014)
Therapeutic potential of tyrosine kinase 2 in autoimmunity
Yan Liang et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2014)
Tyk2 is a therapeutic target for psoriasis-like skin inflammation
Masayuki Ishizaki et al.
INTERNATIONAL IMMUNOLOGY (2014)
JAK-cytokine receptor recognition, unboxed
Randall McNally et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2014)
Regulation of type I interferon responses
Lionel B. Ivashkiv et al.
NATURE REVIEWS IMMUNOLOGY (2014)
A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors
Sue J. Sohn et al.
JOURNAL OF IMMUNOLOGY (2013)
IL-22 Is Required for Imiquimod-Induced Psoriasiform Skin Inflammation in Mice
Astrid B. Van Belle et al.
JOURNAL OF IMMUNOLOGY (2012)
Tyk2 deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice
Masayuki Ishizaki et al.
INTERNATIONAL IMMUNOLOGY (2011)
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Kamran Ghoreschi et al.
JOURNAL OF IMMUNOLOGY (2011)
Natural Killer Cells in Psoriasis
A. M. Tobin et al.
JOURNAL OF INNATE IMMUNITY (2011)
IFN-γ activated JAK1 shifts CD40-induced cytokine profiles in human antigen-presenting cells toward high IL-12p70 and IL-10 production
Michael Conzelmann et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Structure and function of interleukin-22 and other members of the interleukin-10 family
Daniela Barretto Barbosa Trivella et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2010)
Janus kinases in immune cell signaling
Kamran Ghoreschi et al.
IMMUNOLOGICAL REVIEWS (2009)
IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-γ are not
Kerstin Wolk et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2009)
Mechanisms of Disease: Psoriasis.
Frank O. Nestle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation
Hak-Ling Ma et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Expression of Tyk2 in dendritic cells is required for IL-12, IL-23, and IFN-γ production and the induction of Th1 cell differentiation
Naoki Tokumasa et al.
BLOOD (2007)
An important role of Tyk2 in APC function of dendritic cells for priming CD8+ T cells producing IFN-γ
Keiji Aizu et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2006)
Innate and adaptive immunity and the pathophysiology of psoriasis
AA Gaspari
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
Novel functions of tyrosine kinase 2 in the antiviral defense against murine cytomegalovirus
B Strobl et al.
JOURNAL OF IMMUNOLOGY (2005)
Dengue virus type 2 antagonizes IFN-α but not IFN-γ antiviral effect via down-regulating Tyk2-STAT signaling in the human dendritic cell
LJ Ho et al.
JOURNAL OF IMMUNOLOGY (2005)
Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4
WT Watford et al.
IMMUNOLOGICAL REVIEWS (2004)
A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity
MH Shaw et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R
C Parham et al.
JOURNAL OF IMMUNOLOGY (2002)
Partial impairment of interleukin-12 (IL-12) and IL-18 signaling in Tyk2-deficient mice
K Shimoda et al.
BLOOD (2002)
Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12
B Oppmann et al.
IMMUNITY (2000)
Partial impairment of cytokine responses in Tyk2-deficient mice
M Karaghiosoff et al.
IMMUNITY (2000)
Share Paper
